Telo Genomics Corp Cash Flow Conversion Efficiency
Telo Genomics Corp cash flow conversion efficiency. Based on the latest financial reports, Telo Genomics Corp (TELO) has a cash flow conversion efficiency ratio of 11.261x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-300.71K ≈ $-217.53K USD) by net assets (CA$-26.70K ≈ $-19.32K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Telo Genomics Corp (2013–2025)
Cash flow conversion efficiency of Telo Genomics Corp from 2013 to 2025. This chart illustrates how Telo Genomics Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. View TELO share price today for real-time trading data and today's change.
Telo Genomics Corp Cash Flow Conversion Ratio Explained
Telo Genomics Corp cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Telo Genomics Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Telo Genomics Corp ranked by their cash flow conversion efficiency. Also see how much is Telo Genomics Corp worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
City Office
NYSE:CIO
|
0.022x |
|
Tersis Technologies Inc.
NASDAQ:TERS
|
N/A |
|
Mesa Royalty Trust
NYSE:MTR
|
0.162x |
|
Pure Foods Tasmania Ltd
AU:PFT
|
-0.073x |
|
Lupatech S.A
SA:LUPA3
|
-0.220x |
|
T3 Defense Inc.
NASDAQ:DFNS
|
-0.031x |
|
Aberdeen New India Investment Trust PLC
LSE:ANII
|
-0.004x |
|
Immunovia publ AB
ST:IMMNOV
|
-0.870x |
Annual Cash Flow Conversion Efficiency for Telo Genomics Corp (2013–2025)
The table below shows the annual cash flow conversion efficiency of Telo Genomics Corp from 2013 to 2025. Review Telo Genomics Corp (TELO) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | CA$514.98K ≈ $372.53K |
CA$-2.33 Million ≈ $-1.68 Million |
-4.522x | -8.50% |
| 2024-06-30 | CA$590.06K ≈ $426.84K |
CA$-2.46 Million ≈ $-1.78 Million |
-4.168x | -314.10% |
| 2023-06-30 | CA$2.61 Million ≈ $1.89 Million |
CA$-2.63 Million ≈ $-1.90 Million |
-1.006x | -45.96% |
| 2022-06-30 | CA$2.60 Million ≈ $1.88 Million |
CA$-1.79 Million ≈ $-1.30 Million |
-0.690x | -130.08% |
| 2021-06-30 | CA$3.69 Million ≈ $2.67 Million |
CA$-1.10 Million ≈ $-799.00K |
-0.300x | +79.25% |
| 2020-06-30 | CA$775.25K ≈ $560.81K |
CA$-1.12 Million ≈ $-809.87K |
-1.444x | -560.26% |
| 2019-06-30 | CA$-1.04 Million ≈ $-755.83K |
CA$-327.84K ≈ $-237.15K |
0.314x | -96.93% |
| 2018-06-30 | CA$-314.02K ≈ $-227.16K |
CA$-3.21 Million ≈ $-2.32 Million |
10.211x | +387.79% |
| 2017-06-30 | CA$2.23 Million ≈ $1.61 Million |
CA$-7.90 Million ≈ $-5.71 Million |
-3.548x | -2455.34% |
| 2016-06-30 | CA$566.45K ≈ $409.76K |
CA$-78.65K ≈ $-56.89K |
-0.139x | +41.58% |
| 2015-06-30 | CA$449.24K ≈ $324.97K |
CA$-106.77K ≈ $-77.24K |
-0.238x | -233.65% |
| 2014-06-30 | CA$497.97K ≈ $360.22K |
CA$-35.47K ≈ $-25.66K |
-0.071x | +42.83% |
| 2013-06-30 | CA$535.16K ≈ $387.12K |
CA$-66.68K ≈ $-48.23K |
-0.125x | -- |
About Telo Genomics Corp
Telo Genomics Corp., a molecular diagnostics company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions, primarily in Canada. The company's TeloView platform measures the 3D structure and spatial organization of telomeres to inform on genetic and molecular characteristics that are predictive o… Read more